Forsythoside B protects against experimental sepsis by modulating inflammatory factors

Phytotherapy Research

Volumn 26, Issue 7, 2012, Pages 981-987

  Jiang, Wang Lin ^a   Yong Xu, ^a   Zhang, Shu Ping ^a   Zhu, Hai Bo ^b   Jian Hou, ^b  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery Technologies (Luye Pharma Group Ltd)   (China)

Author keywords

caecal ligation and puncture; Forsythoside B; IL 10; NF B; septic shock; triggering receptor expressed on myeloid cells

Indexed keywords

FORYSYTHOSIDE B; HIGH MOBILITY GROUP B1 PROTEIN; IMIPENEM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYELOPEROXIDASE; PROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISEPSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SEPSIS; SMALL INTESTINE; SURVIVAL TIME; UPREGULATION;

ANIMALS; CAFFEIC ACIDS; CELL LINE; GLUCOSIDES; HMGB1 PROTEIN; I-KAPPA B KINASE; IMIPENEM; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; INTESTINE, SMALL; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; MICE; NF-KAPPA B; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84863723893     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3668     Document Type: Review

References (27)

1. Andersson U, Trace KJ,. 2003. HMGB1 in sepsis. Scand J Infect Dis 35: 577-584.
2. Awad SS,. 2003. State-of-the-art therapy for severe sepsis and multisystem organ dysfunction. Am J Surg 186: 23S-30S.
3. Blagbrough IS, Geall AJ, David SA,. 2000. Lipopolyamines incorporating the tetraamine spermine, bound to an alkyl chain, sequester bacterial lipopolysaccharide. Bioorg Med Chem Lett 10: 1959-1962.
4. Bradley PP, Christensen RD, Rothstein G,. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209.
5. Colonna M, Fachetti F,. 2003. TREM-1: a new player in acute inflammatory responses. J Infect Dis 187: S397-S401.
6. Cohen J,. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
7. Delazar A, Sabzevari A, Mojarrab M, et al,. 2008. Free-radical-scavenging principles from Phlomis caucasica. Nat Med (Tokyo) 62: 464-466.
8. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH,. 2003. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660.
9. Jiang WL, Chen XG, Qu GW, et al,. 2009c. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock 32: 608-613.
10. Jiang WL, Chen XG, Zhu HB, Gao YB, Tian JW, Fu FH,. 2009a. Paeoniflorin inhibits systemic inflammation and improves survival in experimental sepsis. Basic Clin Pharmacol Toxicol 105: 64-71.
11. Jiang WL, Chen XG, Zhu HB, Tian JW,. 2009b. Effect of cornuside on experimental sepsis. Planta Med 75: 614-619.
12. Jiang WL, Fu FH, Xu BM, Tian JW, Zhu HB, Jian H,. 2010a. Cardioprotection with forsythoside B in rat myocardial ischemia-reperfusion injury: relation to inflammation response. Phytomedicine 17: 635-639.
13. Jiang Z, Hong Z, Guo W, Xiao YG, Geng FL, Yong NL,. 2004. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 4: 527-537.
14. Jiang WL, Tian JW, Fu FH, Zhu HB, Hou J,. 2010b. Neuroprotective efficacy and therapeutic window of Forsythoside B: In a rat model of cerebral ischemia and reperfusion injury. Eur J Pharmacol 640: 75-81.
15. Kokkola R, Andersson A, Mullins G, et al,. 2005. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9.
16. MacCallum NS, Quinlan GJ, Evans TW,. 2007. The role of neutrophil-derived myeloperoxidase in organ dysfunction and sepsis. Yearb Intens Care Emergency Med 2007: 173-187.
17. Martin-Nizard F, Sahpaz S, Furman C, Fruchart JC, Duriez P, Bailleul F,. 2003. Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity. Planta Med 69: 207-211.
18. Nazemiyeh H, Rahman MM, Gibbons S, et al,. 2008. Assessment of the antibacterial activity of phenylethanoid glycosides from Phlomis lanceolata against multiple-drug-resistant strains of Staphylococcus aureus. Nat Med (Tokyo) 62: 91-95.
19. Oliveira GP, Oliveira MB, Santos RS, Lima LD, Dias CM, Ab' Saber,. 2009. Intravenous glutamine decreases lung and distal organ injury in an experimental model of abdominal sepsis. Crit Care 13: R74.
20. Park JS, Gamboni-Robertson F, He Q, et al,. 2006. High Mobility Group Box 1 protein interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 290: 917-924.
21. Scott MJ, Hoth JJ, Turina M, Woods DR, Cheadle WG,. 2006. Interleukin-10 suppresses natural killer cell but not natural killer T cell activation during bacterial infection. Cytokine 33: 79-86.
22. Suda K, Takeuchi H, Hagiwara T, Miyasho T, Okamoto M, Kawasako, K,. 2010. Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock 33: 526-531.
23. Wang H, Bloom O, Zhang M, et al,. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
24. Wichterman KA, Baue AE, Chaudry IH,. 1980. Sepsis and septic shock: a review of laboratory models and a proposal. J Surg Res 29: 189-201.
25. Yang H, Hreggvidsdottir HS, Palmblad K, et al,. 2010. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107: 11942-11947.
26. Yang H, Tracey KJ,. 2010. Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 149-156.
27. Yao YM, Redl H, Bahrami S, Schlag G,. 1998. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 47: 201-210.